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Received: 21 August 2015 / Accepted: 8 December 2015 / Published online: 21 December 2015
 Springer-Verlag Berlin Heidelberg 2015
Abstract Head and neck cancer patients treated with
high-dose cisplatin and radiotherapy will suffer from
hearing deficits. The current low-dose regimen seldom
causes hearing threshold decrease. Tinnitus in this patient
population has not been investigated earlier. We aimed to
evaluate the possible ototoxicity of low-dose (40 mg/m2)
weekly administered cisplatin with concomitant radio-
therapy. Twenty-two patients with locally advanced head
and neck cancer were prospectively recruited to participate
the study after treatment recommendation for chemora-
diotherapy with low-dose cisplatin and intensity-modulated
radiotherapy. They filled in a Tinnitus Handicap Inventory
and undertook audiologic evaluations before and after
treatment. Ototoxicity was determined by[10 dB thresh-
old shift at frequencies 4 and 8 kHz or in pure tone aver-
age. A historical cohort of nine patients treated with high-
dose (100 mg/m2) cisplatin and radiotherapy was used for
comparison. After treatment, study patients demonstrated
no significant changes in their hearing over frequencies
0.5–4 kHz, and the threshold shifts were minor at 4 and
8 kHz. More than 50 % of patients reported no tinnitus
after treatment and the remainder only had slight to
moderate tinnitus causing no interference with their daily
activities. In contrast, five of the nine patients having
received high-dose cisplatin reported disturbing tinnitus.
Further, changes in pure tone averages were exhibited in
three of these patients and six had significant threshold
shifts at 4 and 8 kHz. Head and neck cancer patients
treated with concomitant intensity-modulated radiotherapy
and low-dose cisplatin seem to experience only minor
audiological sequelae and therefore, these patients appear
to require no routine audiological monitoring. Such eval-
uation could be performed only when needed.
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Introduction
Concomitant chemoradiotherapy (CRT) with cisplatin and
intensity-modulated radiotherapy (IMRT) is considered to
be a standard treatment for head and neck cancer patients
with locally advanced cancer (large tumor or regional
lymph nodes), with inoperable cancer, or as postoperative
treatment in patients with high risk of local recurrence.
IMRT technique allows high and effective radiation doses
to be targeted to the tumor area while minimizing the dose
to vital surrounding tissues such as salivary glands, orbit,
cochlea, and spinal cord. For head and neck cancer patients
IMRT was first introduced in 1997 [1]. It has several
advantages, but requires experienced and careful planning
in the complicated anatomical sites of the head and neck
area [2]. At the Helsinki University Hospital, IMRT has
been used in the treatment on head and neck cancer
patients since 2000 [3–5]. In the management of these
patients, we have used mainly weekly given low-dose
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cisplatin (40 mg/m2) as our standard protocol treatment
since the year 2000 to avoid the toxicity of high-dose
cisplatin regimens.
Cisplatin is widely used as a chemotherapeutic agent for
head and neck, and other cancers. Cisplatin-based
chemotherapy, however, can potentially cause permanent,
binaural, sensorineural, high-frequency hearing loss (HL),
and tinnitus. In addition to its ototoxicity, cisplatin is also
nephro- and neurotoxic. Underlying HL and age increase
the risk of post-treatment HL [6]. Cisplatin-induced oto-
toxicity is also dose-dependent [7]. Severe outer hair cell
loss, in particular in the basal and middle turns of the
cochlea, is seen in animals treated with high doses of cis-
platin [8].
Head and neck cancer patients receiving protocol
treatment including high-dose (100 mg/m2) cisplatin every
3 weeks will suffer HL [9–11]. This higher dose cisplatin is
associated with significantly more acute toxicity, including
ototoxicity, than, for example, the alternative lower dose,
daily-administered two courses of cisplatin and 5-fluo-
rourasil, with concurrent radiotherapy [12]. This HL is both
subjective and objective [13]. High-dose cisplatin-based
CRT also causes more sensorineural HL than radiotherapy
alone [14]. Accelerated radiotherapy does not seem to
damage the ear. In particular, radiation doses 40 Gy or less
to the cochlea without chemotherapy fail to cause clinically
significant HL [6, 11]. No previous reports exist on tinnitus
caused by the standard treatment protocol using low-dose
cisplatin (40 mg/m2).
In this study, we compared hearing and tinnitus results
in head and neck cancer patients treated with 6 weekly
courses of low-dose cisplatin (40 mg/m2) with a cohort of
patients who had been treated with three courses of high-
dose cisplatin (100 mg/m2) every 3 weeks with concomi-
tant IMRT. Based on our clinical experience, we hypoth-
esized that the lower dose cisplatin-based CRT would
cause less ototoxicity.
Patients and methods
The study was conducted at the Departments of Oto-
laryngology-Head and Neck Surgery and Oncology, Hel-
sinki University Hospital (HUH), Helsinki, Finland
between 2010 and 2013. The Research Ethics Board at the
HUH approved the study protocol. All patients were
prospectively recruited to participate after evaluation and
treatment recommendation by a multidisciplinary tumor
board. Patients signed an informed consent before partici-
pation. Twenty-nine patients with locally advanced head
and neck cancer and treatment recommendation for CRT
participated the prospective part of the study. They
received low dose weekly cisplatin 40 mg/m2 and
concurrent IMRT. Patients completed the Tinnitus Handi-
cap Inventory (THI) [15] and underwent hearing and
emission examinations before and after CRT. The post-
treatment audiogram was performed in median 8 months
after CRT treatment (range, 3–19). Seven patients had only
baseline audiologic tests: five died and two were lost dur-
ing the follow-up. Therefore, 22 patients with a mean age
of 61 years (range, 40–74) were able to complete the study.
For comparison, retrospective data were gathered for nine
head and neck cancer patients who had been treated with
100 mg/m2 cisplatin-based CRT. Their mean age was
58 years (range, 41–81).
Most of the study patients received a total dose of 70 Gy
(mean 68.5; range, 60–70) IMRT. There were 10 patients
who were able to complete all the intended six courses of
weekly 40 mg/m2 cisplatin treatment, 8 patients received 5
courses, 2 patients 4, one patient received 3 courses, and 1
patient 2 cisplatin treatments (Table 1). In the comparison
group with 9 patients, a mean total radiation dose was
66 Gy (range, 50–72). Of these patients, six were treated
with IMRT and only three with conventional 3-D radio-
therapy. In addition, for these three patients CT-based
treatment planning was used and their cochlear dose did
not exceed 40 Gy. Four (44 %) of these patients could
complete the intended chemotherapy. The primary site of
the tumor in the study group was either in hypopharynx
(n = 3), larynx (3), tonsil (5), tongue (1), base of tongue
(6), nasopharynx (1), or nasal cavity (1), and 2 patients had
an unknown primary site. The tumor was staged T3-4 in 7
patients, T2 in 10, and T1 or T0 with regional pathological
lymph nodes in 5 patients.
All patients underwent pretreatment audiometry as a
baseline study. Pure tone audiometry was performed in a
sound booth using Aurical Plus Audiometry (Otometrics,
Denmark). Thresholds over frequencies from 125 Hz to
8 kHz were measured. Mean thresholds over the frequen-
cies 0.5–4 kHz (pure tone average, PTA) and thresholds at
4 and 8 kHz were calculated. Transient otoacoustic emis-
sions (TEOAE, ILOV6) were performed before and after
treatment. They were analyzed for emission levels signal to
noise ratio (S/N) and reproducibility for the whole wave
response and for frequency bands at 1.0, 1.4, 2.0, 2.8, and
4.0 kHz. All hearing testing measurements were performed
by the same licensed audiologist. The audiograms were
analyzed before and after treatment for sensorineural
changes at 0.5–4 kHz (PTA) and at 4 and 8 kHz. A sig-
nificant hearing loss change (criteria for ototoxicity) was
defined as a decrease of C10 dB at 4 and 8 kHz or in PTA.
For tinnitus measurement, we used tinnitus handicap
inventory (THI), which is a self-administered questionnaire
to help determine the degree of distress experienced by the
patient. The severity of tinnitus is classified from slight to
catastrophic and the grading from 1 to 5 accordingly. The
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scores vary between 0 and 100. Patients were asked to fill
in the questionnaire before and after CRT treatment [15]. A
minimum clinically significant change in the THI score can
be defined by a difference of 7 points either up- or
downwards [16].
Results
Twenty-two patients (17 males) completed the prospective
study. Their mean age was 61 years (range 40–74). Low-
dose cisplatin with concurrent IMRT was well tolerated.
Eighty percent of the study patients were able to receive
5–6 courses of low-dose cisplatin treatment.
The study patients’ hearing results are presented in the
Table 1. None of them had significant post-treatment
threshold shifts in PTA over frequencies from 500 to
4 kHz. Minor changes were seen at the higher frequencies
at 4 and 8 kHz and the maximum (20 dB) threshold shift at
8 kHz. Median audiologic follow-up time between the
baseline audiogram and post-treatment audiogram was
8 months (range 3–19).
We tested the statistical significance of the differences
between the tinnitus results in these two groups with
Fisher’s Exact Test (2-sided) and found a p value of 0.001
when comparing one out of the 22 patients having mod-
erate tinnitus in the low-dose cisplatin group and six out of
the nine patients in the high-dose cisplatin group reporting
disturbing tinnitus. After CRT, eight (36 %) study patients
had slight or mild tinnitus, one patient had moderate tin-
nitus, and all the other 13 (59 %) did not report either
having tinnitus or suffering from a tinnitus experience. One
person with earlier onset occupational noise exposure
induced tinnitus scored less in the THI, i.e. his tinnitus was
less disturbing after CRT. Another patient experienced
tinnitus (score 48) before treatment, but post-treatment
tinnitus was only of slight level (score 16). Tinnitus did not
predict change in hearing levels. The post-treatment tin-
nitus results are presented in the Table 1 and it demon-
strates changes in THI scores before and after treatment.
Kidneys of these patients tolerated the low dose treatment
well. There were two study patients who received 5 courses
of cisplatin instead of six because of signs of
nephrotoxicity.
Table 1 Patient and treatment characteristics, post-treatment hearing and tinnitus results, and status at the last follow-up in 22 patients treated














1/M 70/6 No 10 dB (8) Mild (18) NED 18
2/M 70/6 No 10 dB (8) Slight (0) NED 0
3/M 70/6 No No No (0) DOD 0
4/M 70/6 No 15 dB (4) No (0) NED 0
5/M 70/2 No no Mild (20) NED 20
6/M 70/6 No 20 dB (8) No (0) NED 0
7/F 70/5 No No No (0) AWD 0
8/F 70/5 No 10 dB (8) No (0) NED 0
9/F 60/6 No No No (0) AWD 0
10/M 70/4 No 10 dB (4) No (0) NED 0
11/M 66/6 No No No (0) NED 0
12/M 60/6 No No Slight (2)a NED -6
13/M 70/6 No No Slight (14) DOD 14
14/M 70/6 No No Slight (16)a NED -32
15/M 70/5 No 20 dB (8) Slight (2) NED 2
16/M 70/4 No 10 dB (8) No (0) NED 0
17/M 70/5 No 10 dB (4) No (0) NED 0
18/M 60/5 No No Slight (0) NED 0
19/M 70/5 No No No (0) NED 0
20/F 70/5 No No Moderate (44) NED 44
21/M 70/5 No 10 dB (8) No (0) DOD 0
22/F 70/3 No No No (0) NED 0
M male, F female, Radiation dose in Gy, NED no evidence of disease, AWD alive with disease, DOD dead of disease
a Less disturbing tinnitus after treatment than at the baseline and the meaningful responses are marked with bold text
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The historical high-dose cisplatin group comprised nine
head and neck cancer patients who had been treated with
100 mg/m2 cisplatin with concurrent radiotherapy. Toxicity-
related symptoms led to cessation of treatment in over 50 %
of these patients. Seven out the nine patients in this group
developed HL in the higher frequencies and four of them had
significant changes in their PTA. Six out of the nine patients
reported onset of disturbing tinnitus after CRT.
Discussion
In the present prospective cohort study, head and neck
cancer patients treated with weekly low-dose cisplatin
(40 mg/m2) and concomitant IMRT had only minor HL
and tinnitus. Whereas most head and neck cancer patients
treated with high-dose cisplatin (100 mg/m2) had hearing
threshold shifts in the higher frequencies and four had also
changes in their PTA. Earlier reports have shown that CRT
with high-dose cisplatin (100 mg/m2) is a significant risk
factor for high-frequency HL [9, 11–13, 17]. Use of lower
dose cisplatin-based CRT has decreased the risk of clini-
cally significant HL [11, 12]. In addition, long-term minor
progression in hearing impairment after treatment of high-
dose cisplatin has been reported [9]. Our results are in line
with earlier reports and suggest that the cisplatin ototoxic
effects are dose-dependent. More importantly, the present
study is the first to evaluate tinnitus experience in this
patient population receiving the current protocol treatment
using weekly administered low-dose cisplatin.
In earlier reports, the use of radiotherapy alone in head
and neck cancer patients has not been deteriorating to the
inner ear [6]. In particular, radiation doses of 40 Gy or less
to the cochlea have not resulted in clinically significant HL.
Hitchcock et al. have recommended the use of low-dose
weekly administered cisplatin when possible. Further,
IMRT is favored in order to avoid excess cochlear radiation
in the treatment of head and neck cancer patients [11]. In
this study, all the patients were treated with IMRT tech-
nique up to the total dose of 70 Gy.
Cisplatin-induced post-treatment tinnitus in head and
neck cancer patients has been scarcely studied and the
mechanism remains unknown. In animal studies, loss of
outer hair cells (OHC) function has been suggested to be an
important factor and maybe a trigger of tinnitus-related
hyperactivity in the dorsal cochlear nucleus (DCN). The
nucleus activity can also be caused by direct toxic effect of
cisplatin on the DCN, independent of the effect on OHCs
[18, 19]. Both OHC and inner hair cells were damaged after
topical injection of cisplatin to the round window [20].
The present post-treatment THI results varied from no
tinnitus to moderate, i.e., the patients experienced no tin-
nitus as a problem after low-dose cisplatin treatment.
During the treatment, only one of the study patients failed
to complete the planned 6th cisplatin dose because of
severe tinnitus, but by the time of filling in the THI
questionnaire, his tinnitus was only slight. Four of the
study patients had significantly higher scores in THI after
treatment, nonetheless, three patients’ self-perceived tin-
nitus handicap was mild in severity and one patient expe-
rienced moderate tinnitus. She had nasopharyngeal
carcinoma and her Eustachian tubes were obstructed post-
treatment, probably causing a more disturbing tinnitus
experience. After CRT, two patients had decreased THI
scores, of which one was clinically significant (Table 1).
There is no consensus definition for ototoxicity in the
literature, and this fact makes comparison of various study
results difficult [21]. American Speech-Language-Hearing
Association criteria refer to a threshold shift of C20 dB at
one frequency or a shift C10 dB at two or consecutive
frequencies [22]. Simpson et al. found multiple frequencies
averaging above 8000 Hz, and also multiple frequency
averages between 3000 and 8000 Hz, useful in monitoring
the ototoxic effects of cisplatin. This method takes normal
variability in hearing threshold levels into account [23]. A
criterion of C10 dB threshold shift at C2 adjacent fre-
quencies tested in (1/6)-octave steps was useful in moni-
toring ototoxicity. If tested 1/2-octave step size, the best
results in monitoring were achieved for shifts C15 dB at
one or more frequencies. Thus, the smaller frequency steps
improved test performance [24].
Hitchcock et al. defined clinically significant HL as a
C10 dB loss [11]. Ototoxicity can be determined by
comparing the audiologic baseline evaluations with post-
treatment results. Significant clinical change occurs when
the threshold shifts between reliable measurements exceed
normal variability [25]. In our study, a significant HL
change and therefore criteria for ototoxicity, was defined as
a decrease of C10 dB at 4 and 8 kHz or in PTA. These
criteria are quite strict and confirm that low-dose cisplatin
is well tolerated and causes only minimal if any HL that
could be measured with existing clinical equipment.
In the present study, TEOAE failed to prove to be a
useful tool in monitoring ototoxicity. One reason for this
could be that TEOAE fails to measure high frequencies,
but is able to calculate more frequencies between 1 and
4 kHz. Our emission results showed no deterioration after
treatment. This might be explained by the fact that the ears
tolerate low-dose cisplatin well, as was seen in audiograms
PTA (0.5–4 kHz). Therefore, the TEOAE findings, without
deterioration of emission levels signal to noise ratio (S/N)
and reproducibility, could also confirm the present audio-
gram results. We decided to use the TEOAE instead of
distortion-product otoacoustic emissions (DPOAE)
because TEOAE is in frequent clinical use at our institution
and thus we feel confident in interpreting the results. Other
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studies have proved that DPOAE could be a better tool for
monitoring ototoxicity [7, 26]. It has proved to be extre-
mely sensitive and superior to TEOAE [26]. In addition,
ultra-high-frequency audiometry technique could identify
ototoxic damage earlier than conventional audiometry [25].
Monitoring and early detection of ototoxicity is considered
beneficial in order to minimize or prevent communication
impairment. If HL changes are seen, alternative treatment
dosages or medications can be considered, or the patient
can be prepared to cope with hearing impairment. If no HL
is identified, the planned aggressive cancer treatment can
be continued [25].
The present findings are novel and promising, but they
must be interpreted cautiously. The number of study
patients was limited and the historical group even smaller.
We used strict ototoxicity criteria, which led to the iden-
tification of even small changes in audiograms. In the
detection of minimal ototoxic effects, extended high-fre-
quency audiometry and DPOAE could have been more
sensitive. Additional audiological testing could have con-
firmed our results, but these patients are experiencing
treatment related side effects and therefore are unsuit-
able for repeated examinations. The strengths of the study
are the prospective setting and unambiguous finding with
no significant PTA shift in the study population. Therefore,
we do not recommend routine screening of hearing after
low-dose cisplatin treatment and concurrent IMRT. Audi-
ologic testing could be performed if the patients have
symptoms, such as subjective HL or tinnitus.
Conclusion
Low-dose (40 mg/m2) cisplatin-based CRT was well tol-
erated with only mild toxic side effects and most of the
study patients completed the CRT as planned. In PTA,
there were no significant threshold shifts and only minor
changes at frequencies of 4 and 8 kHz. TEOAE failed to
help in ototoxicity monitoring. After low-dose weekly
administered cisplatin with IMRT, over 50 % of the study
patients had no tinnitus and all the rest only had slight
tinnitus that caused no interference in their daily activities.
Therefore, the number of study patients with clinically
significant ototoxicity was minimal, suggesting that audi-
ologic evaluation is likely not necessary in patients treated
with low-dose cisplatin-based CRT. High-dose cisplatin
with concomitant RT demonstrated significantly more
toxicity, including hearing loss and tinnitus. It is important
to be aware of the risk of ototoxicity in cisplatin treated
patients. More importantly, audiological monitoring and
rehabilitation should be started without delay, to minimize
progression of communication problems in the head and
neck cancer patients managed with chemotherapy.
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